TIANJIN, China, March 23, 2021 /PRNewswire/ — CanSinoBIO Biologics Inc. (“CanSinoBIO”) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for

The company said in a regulatory filing that it plans to enter Phase II development “soon” and on Friday had already posted a page for the study, which will take

CanSino Biologics (CanSinoBIO) is expected to increase the annual production capacity of its recombinant adenovirus vector COVID-19 vaccine – the only single-dose vaccine approved in China – to 200 to

Brief: Qiming’s portfolio company CanSino Biologics Inc. (SHSE: 688185, HKEX: 06185) announced that its Recombinant Novel Coronavirus Vaccine (“Ad5-nCoV”, trade name: Convidecia) had obtained a Good Manufacturing Practice (GMP) certificate